BioStock: CEO Saniona »The real growth will come from our proprietary projects«

Danish biotech Saniona recently presented positive topline results from a clinical phase II study in hypothalamic obesity (HO), one of several rare eating disorders and obesity related indications the company is currently pursuing. BioStock connected with CEO Rami Levin, in Boston, for a video interview in which he expands on the HO study results, Saniona’s financing strategy and the next steps required to drive the primary asset Tesomet towards commercialization.

Watch the full video interview at biostock.se: 

https://www.biostock.se/2020/05/ceo-saniona-the-real-growth-will-come-from-our-proprietary-projects/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se